Core Points - 23andMe has filed for Chapter 11 bankruptcy protection, leading to concerns about the future of customer genetic data [4][6] - The company's co-founder and CEO, Anne Wojcicki, has resigned and plans to bid on the company during the bankruptcy sale process [5] - Privacy experts are advising users to consider deleting their data due to potential risks from new ownership and hackers [3][7] Company Situation - The bankruptcy filing aims to facilitate the sale of substantially all assets and reduce operational costs by rejecting certain lease contracts [6] - 23andMe intends to continue operations during the bankruptcy process [6] - The company has faced previous data breaches, including a 2023 incident that exposed the genetic data of nearly 7 million customers [8] Data Privacy Concerns - Experts highlight the sensitivity and value of genetic data, emphasizing that it is unique to each individual [9][10] - 23andMe claims it does not share data with health insurance companies or employers without user consent, but there are concerns about how data can still be used for targeted advertising [10][11] - California Attorney General has issued alerts regarding users' rights to delete their data amid the company's financial distress [12] User Data Management - Users can delete their data by accessing account settings and following specific steps to confirm deletion [13] - Users can also request the destruction of their saliva samples and withdraw consent for third-party research [14]

DNA testing pioneer 23andMe filed for bankruptcy — sparking fresh concerns about safeguarding the personal data of the company’s more than 15 million customers.The former Silicon Valley darling sought Chapter 11 protection on Sunday after struggling with weak demand for its ancestry testing kits that once featured in Oprah Winfrey’s annual list of favorite things, and following a 2023 data breach that damaged its reputation. 7 DNA testing pioneer 23andMe, one of Silicon Valley’s most recognized biotech st ...

Ginkgo Bioworks Holdings, Inc. (DNA) closed the latest trading day at $7.27, indicating a +1.39% change from the previous session's end. The stock exceeded the S&P 500, which registered a gain of 0.08% for the day. On the other hand, the Dow registered a gain of 0.08%, and the technology-centric Nasdaq increased by 0.52%.Coming into today, shares of the company had lost 37.27% in the past month. In that same time, the Medical sector lost 1.03%, while the S&P 500 lost 7.33%.Investors will be eagerly watching ...

Ginkgo Bioworks Holdings, Inc. (DNA) has been beaten down lately with too much selling pressure. While the stock has lost 52.3% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum ...

Welcome back to TechCrunch Mobility — your central hub for news and insights on the future of transportation. Sign up here for free — just click TechCrunch Mobility!TechCrunch’s transportation team — well at least myself and senior reporter Rebecca Bellan — are hittin’ the road. Destination: SXSW, the annual tech, music, film, and culture conference in Austin. We both have panels and if you’re at SXSW, please come check these out and introduce yourself.  We’ll be keeping our eyes and ears open for transpor ...

Core Viewpoint - Ginkgo Bioworks Holdings, Inc. (DNA) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks rating system is based on the changing earnings picture of a company, specifically tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - Ginkgo Bioworks is projected to earn -$5.06 per share for the fiscal year ending December 2025, reflecting a 51.2% change from the previous year's reported number [9]. - Over the past three months, the Zacks Consensus Estimate for Ginkgo Bioworks has increased by 17.7%, indicating a positive trend in earnings estimates [9]. Impact of Institutional Investors - Changes in earnings estimates are strongly correlated with stock price movements, largely due to institutional investors who adjust their valuations based on these estimates [5]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, which subsequently affects stock prices [5]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of Ginkgo Bioworks to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [11].

-          EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the globe-          EffiX™ delivers high-yield production across multiple modalities, achieving titers of over 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNAHANGZHOU, China, March 3, 2025 ...

Ginkgo Bioworks (NYSE: DNA ) remains focused on reducing cash burn and made significant progress in this area in the fourth quarter of 2024. While this is a positive, Ginkgo lacks direction, and its newer Cell Engineering offerings have demonstrated limitedRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by ident ...

Grow with Ginkgo Q4 and FY 2024 Update & Business Review February 25, 2025 Property of Ginkgo Bioworks — 1 Q1 2024 UPDATE & BUSINESS REVIEW Disclaimer FORWARD-LOOKING STATEMENTS This presentation, the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, incl ...

Financial Data and Key Metrics Changes - Ginkgo Bioworks ended Q4 2024 with $562 million in cash and no bank debt, significantly reducing cash burn to $55 million from $114 million in Q3 2024 [10][32][48] - Total company adjusted EBITDA for Q4 was negative $57 million, an improvement from negative $101 million in Q4 2023, with full-year adjusted EBITDA at negative $293 million, up from negative $365 million in 2023 [30][31][32] Business Line Data and Key Metrics Changes - Cell Engineering revenue reached $35 million in Q4 2024, a 29% increase year-over-year, with full-year revenue at $174 million, down 10% from 2023 when excluding a one-time noncash revenue impact [15][17] - Biosecurity revenue was $9 million in Q4 2024, down from $53 million in 2023, reflecting a 51% decline due to the end of K-12 COVID testing contracts [23][24] Market Data and Key Metrics Changes - The company reported a total of 138 active programs across 85 customers in the Cell Engineering platform, a 5% increase year-over-year [17] - The government segment has been a strong source of growth, although uncertainties in this area are factored into revenue guidance [38][40] Company Strategy and Development Direction - Ginkgo aims to reach adjusted EBITDA breakeven by mid-2026 while maintaining a cash margin of safety, focusing on cost reductions and expanding revenue sources [10][43] - The company is expanding into life science tools and services, responding to market trends in biopharma for more data to support AI models [44][65] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging biotech R&D market but expressed optimism about the potential of new tools offerings and the government segment [38][39] - The company is taking a conservative approach to revenue guidance for 2025, estimating Cell Engineering revenue between $110 million and $130 million and Biosecurity revenue at least $50 million [39][40] Other Important Information - Ginkgo has remediated its SOX material weakness, indicating improved financial reporting processes [43] - The company has achieved a $190 million annualized run rate reduction in spending compared to Q1 2024 [47] Q&A Session Summary Question: What are the ideal customer personas Ginkgo needs to close for new client acquisition? - The ideal customer persona varies by product; for solutions deals, it is typically the head of R&D in large biopharma or the CEO in small biotechs. For data points, it is usually a lead for a drug program, and for automation, it is automation leads responsible for building out new setups [88][90][91]